EU science collaboration

13 November 2017

The Chief Executive of the Russell Group of universities Dr Tim Bradshaw today said there is consensus across Europe that protecting international scientific collaboration must be a Brexit priority.

Dr Bradshaw’s comments came as the Guild of European Research-Intensive Universities published a Brexit statement which argued ensuring the welfare of Europe’s economies requires more collaboration in research and innovation, not less.

Speaking days after the latest round of Brexit negotiations closed in Brussels, Dr Bradshaw said there are compelling reasons for joint working between universities and research partners across Europe to continue after Brexit.

Commenting, Chief Executive of the Russell Group Dr Tim Bradshaw said:

“There is consensus across Europe that protecting international scientific collaboration must be a Brexit priority. The Russell Group have not met anyone on either side of the talks who does not see the value of maintaining academic links after the UK leaves the EU. We need the negotiating teams to work together and deliver a deal that reflects the priorities set out in this statement from the Guild of European Research-Intensive Universities.

“We want to build on the networks that have been established with universities, staff and students across Europe over the last 40 years. There are compelling economic, social and cultural reasons for this work to continue after Brexit.

“Changes to the relationship between the UK and the EU are inevitable. New barriers to the movement of ideas, academics and students are not. A comprehensive Brexit agreement on science and innovation is in everyone’s best interests.”

Further information on the statement from the Guild of European Research-Intensive Universities is available online here. 

Related case studies

International project aims to understand severe coronavirus infections

Read more >

Developing new antibiotics to manage chronic lung infection

Researchers at Queen’s University Belfast are leading a €50 million Europe-wide project to develop new inhaled drug treatments for cystic fibrosis and bronchiectasis.

 

Read more >